To further figure out the oncogenic role of JMJD6 in RCC, we analyzed several cohorts to evaluate its clinical significance and found that JMJD6 was commonly higher in tumor samples than in normal tissues from the TCGA‐KIRC cohort, GSE40435, GSE53757, and IGC‐RCC cohort (Figure 2A–D). This evidence concerns the gene JMJD6 and renal cell carcinoma.